Dr Peter Jackson, Executive Director, INFEX Therapeutics Ltd

Dr Peter Jackson is an experienced UK-based serial entrepreneur in the life sciences sector. Over the past 15 years, he has created seven new companies, targeting novel therapeutics across infection, oncology and immunology, as well as in agrochemicals and life sciences services.  Two of these companies are currently admitted to trading on AIM: Redx Pharma PLC and Bivictrix Therapeutics PLC.

Dr Jackson has over 25 years’ experience in the sector, previously holding senior executive roles as commercial director and then Vice President of Avecia’s Pharmaceutical Products business unit, following senior commercial and R&D positions at predecessor companies Zeneca and ICI.

Dr Jackson is a member of the Project Advisory Group for NHS England and NICE on the new UK antibiotic reimbursement trial and is a member of a UKRI/BBSRC panel reviewing academic AMR investments and cross-departmental AMR strategy.  He is also a special advisor on AMR and pandemic preparedness to the Washington DC-based Milken Institute. Dr Jackson has recently joined the board of the BEAM Alliance, a network of European AMR biotech companies lobbying for the implementation of AMR drug reimbursement reforms in the EU.